Accueil   Diary - News   All news GeNeuro’s temelimab shows extended neuroprotective effects in relapsing-remitting MS

GeNeuro’s temelimab shows extended neuroprotective effects in relapsing-remitting MS

 

  • Further evidence adds to already strong set of positive clinical data

 

  • Data presented at ECTRIMS 2019 Congress in Stockholm, Sweden

 

 

Geneva, Switzerland, September 16, 2019 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes (T1D), today announced that the neuroprotective effects of temelimab in MS patients extend to 96 weeks and that it is safe to use and well tolerated for a prolonged period. These data, from ANGEL-MS, an extension of the Phase 2 CHANGE-MS trial in relapsing-remitting MS (RRMS), were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2019) Congress in Stockholm, Sweden.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree